drugset / Trial / NCT04793204

A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects

NCT04793204

Phase 1 Completed 16 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of fezolinetant after single-dose and multiple dose administration in healthy Chinese female participants.

Timeline

Start
2021-03-24
Primary completion
2021-05-21
Completion
2021-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Fezolinetant Small molecule Oral

Indications

No indication recorded.